Abstract
Background Calculations of disease burden of COVID-19 are used to allocate scarce resources and historically have focused on mortality, with little attention to morbidity such as postviral ‘post-COVID,’ similar to chronic fatigue syndrome (CFS), which strikes 4 and 16% of male and female survivors. This paper quantifies post-COVID disability burden and combines it with case fatality to estimate total morbidity per COVID-19 case.
Methods Healthy life years lost per COVID-19 case were computed as the sum of (incidence*disability weight*remaining lifespan) for death and post-COVID (modeled as CFS) by sex and 10-year age category. In addition to death, the main model considered lifelong mild, moderate or severe CFS; Model 2, CFS which resolved in ten years; Model 3, no CFS but 10% risk of death 10 years later.
Results In all models, acute mortality was only a small share of total morbidity. For lifelong moderate CFS symptoms, healthy years lost per COVID-19 case ranged from 0.92 (male in his 30s) to 5.71 (girl under 10) and were 3.5 and 3.6 for the oldest females and males. At higher symptom severities, young people and females bore larger shares of total morbidity; if symptoms were persistent or survivors’ later mortality increased, young people of both sexes were at highest risk.
Conclusions Compared to post-COVID, acute mortality contributes only a small share of total COVID-19 morbidity. Total burden falls heavily on the young, who are currently deprioritized for preventive interventions such as vaccines. To fairly allocate scarce resources, decisionmakers should consider all morbidity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
no funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No human subjects involved
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are publicly available at the links in the manuscript; worldometers.info
